When was Orum Therapeutics founded?

Orum Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Orum Therapeutics located?

Orum Therapeutics is headquartered in Daejeon, South Korea.

How many employees does Orum Therapeutics have?

As of Jul 31, 2026, the latest employee count at Orum Therapeutics is 54.

Is Orum Therapeutics a funded company?

Orum Therapeutics is a funded company, having raised a total of $92M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 14, 2017.

When was the latest funding round of Orum Therapeutics?

Orum Therapeutics' latest funding was a $***** Post IPO round on Dec 18, 2025, with participation from 10 investors.

Where does Orum Therapeutics rank among its competitors?

Orum Therapeutics ranks 169th amongst 3296 active competitors, of which 1129 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Orum Therapeutics?

Orum Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Orum Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of cell-penetrating antibodies as oncology therapeutics. It has a proprietary cell-penetrating antibody technology and is developing monoclonal antibodies to directly target the activated form of RAS. The cell-penetrating technology develops antibodies that can access the cytosol of living cells following receptor-mediated endocytosis. RAS proteins function to transmit signals within cells that control cell growth, differentiation, and survival. The product pipeline includes ORM-5029, ORM-6151, and ANDC-0001 for solid tumors and hematological cancers

Website: www.orumrx.com/
Social

Key Metrics

Founded Year

2016

Location

Daejeon, South Korea

Stage

Public

Total Funding

$92M in 4 rounds

Latest Funding Round

Post IPO, Dec 18, 2025, $*****

Investors

IMM Investment & 20 more

Ranked

169^th among 3296 active competitors

Employee Count

54 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3042 more

Exit Details

Public

View Orum Therapeutics' full profile

Orum Therapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ORUM THERAPEUTICS USA, INC. CIN: 833300238 , United States, Active	Dec 31, 1999	-	23 (As on Dec 31, 2024)	-
Orum Therapeutic Co., Ltd. CIN: 887-81-00503 , South Korea, Active	Aug 16, 2016	-	-	-

Orum Therapeutics got listed on Feb 14, 2025.

Click here to take a look at Orum Therapeutics's IPO in detail

Orum Therapeutics has raised a total funding of $92M over 4 rounds. Its first funding round was on Jun 14, 2017. Its latest funding round was a Post IPO round on Dec 18, 2025 for $*****. 10 investors participated in its latest round. Orum Therapeutics has 21 institutional investors.

Here is the list of recent funding rounds of Orum Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 18, 2025	8710949	Post IPO	7086109	5514154	2067611	9531325
Jun 23, 2021	9222935	Series B	6766790	3519368	8669671	KDB Investment & 3 more
Jul 17, 2019	9895870	Series B	5256852	6947664	IMM Investment & 3 more	Solidus Investment & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Orum Therapeutics's funding rounds and investors

The founders of Orum Therapeutics is Yong Sung Kim.

Here are the details of Orum Therapeutics' key team members:

Yong Sung Kim: Co-Founder of Orum Therapeutics.

View details of Orum Therapeutics's Founder profiles and Board Members

Orum Therapeutics' employee count trend

Orum Therapeutics has 54 employees as of Jul 26. Here is Orum Therapeutics's employee count trend over the years:

Employee count trend for Orum Therapeutics

Uncover Orum Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orum Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Orum Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
169th	Orum Therapeutics 2016, Daejeon (South Korea), Public	Developer of cell-penetrating antibodies as oncology therapeutics	$92M	KTB Network, Smile Gate Investment & 19 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Orum Therapeutics's competitors? Click here to see the top ones

Orum Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Orum Therapeutics's geography:

Free

South Korea Tech Annual Funding Report

Edition: 2025 (44 Pages)

View all reports related to Orum Therapeutics

Media has covered Orum Therapeutics for a total of 9 events in the last 1 year, 4 of them have been about company updates and 3 about people movement.